Natalizumab greatly reduces inflammatory relapses in multiple sclerosis (MS) by blocking the integrin-mediated leukocyte traffic to the brain, but less is known about its effects on the systemic immunity. We measured 48 cytokines/chemokines in sera from 19 natalizumab-treated MS patients. Serum concentrations of both anti-(IL-10, IL1ra) and pro-inflammatory (IL7, IL16) molecules decreased after 21-month treatment, without associations to unbalanced Th2/Th1cytokine ratios, clinical responses, and blood/urine replication of polyomavirus JC (JCPyV). No patient developed the JCPyV-related progressive multifocal leukoencephalopathy (PML), the major risk factor of natalizumab therapy. Our data suggest that natalizumab has marginal impact on the systemic immunity.
Introduction
The transmigration of autoreactive-activated T cells from peripheral blood into the central nervous system (CNS) is a crucial step in the initiation and maintenance of brain inflammatory reaction in multiple sclerosis (MS) (Steinman et al., 2002) . The α4β1-integrin (VLA-4), expressed on the leukocytes' surface and interacting with the vascular cell adhesion molecule 1 (VCAM-1), is critically involved in this process because it mediates both the adhesion and migration of lymphocytes across the blood-brain barrier (BBB) (Kumar et al., 2005; Kummer and Ginsberg, 2006; Libbey and Fujinami, 2010; Polman et al., 2006; Rose et al., 2002; Sawcer et al., 2011) .
Natalizumab is a monoclonal antibody directed against the α4 chain of the VLA-4 and α4β7 integrins and is used as a monotherapy for treating relapsing-remitting MS (RRMS)· (Stuve and Bennett, 2007) . Natalizumab substantially reduces the relapse rate and the worsening symptoms, but its use is associated the development of progressive multifocal leukoencephalopathy (PML), a fatal demyelinating disease that occurs due to the lytic replication of the Polyomavirus JC (JCPyV) (Polman et al., 2006) .
Chemokines affect the trafficking of leukocytes to the sites of inflammation and have a crucial role in establishing a balance between subpopulations of T helper (Th) cells (Baggiolini, 1998). Th2-related cytokines are associated with inflammatory reduction and improvement of MS symptoms. In contrast, Th1-related cytokines, which are known as pro-inflammatory proteins are increased in brain, cerebrospinal fluid (CSF) and/or blood of MS patients, especially during acute exacerbations (Imitola et al., 2005; Mellergard et al., 2010; Miller et al., 2004; Sharief and Hentges, 1991) .
The effects of the cytokine/chemokine levels have been occasionally analyzed, with contrasting results (Khademi et al., 2009; Kivisakk et al., 2009; Mellergard et al., 2010; Ramos-Cejudo et al., 2011) . To gain increased insight into the immunomodulating effect of natalizumab systemically, we used a multiplex array to measure the levels of 48 cytokines/chemokines in sera from MS patients treated with natalizumab from 21 months.
Materials and methods

Patients and samples collection
After obtaining signed, informed consent based on the local ethics committee guidelines, 19 patients with RRMS, treated with natalizumab, were enrolled at the "Fondazione Istituto Neurologico C. 
